Altimmune (ALT) Change in Account Payables (2010 - 2026)

Altimmune (ALT) has reported Change in Account Payables for 17 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables fell 237.07% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at $453000.0 (up 116.88% YoY), while the FY2025 annual figure was $2.5 million, up 234.8% from the prior year.
• Change in Account Payables grew to -$1.2 million in Q1 2026 per ALT's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $4.0 million in Q3 2025 and bottomed at -$2.1 million in Q4 2025.
• Historically, Change in Account Payables has averaged -$29647.1 across 5 years, with a median of -$922000.0 in 2024.
• Annual changes were most pronounced in 2023 — Change in Account Payables sank 280.36% — and 2025, when it soared 354.21%.
• Altimmune's Change in Account Payables stood at $3.4 million in 2022, then slumped by 128.83% to -$976000.0 in 2023, then increased by 5.53% to -$922000.0 in 2024, then plunged by 126.36% to -$2.1 million in 2025, then surged by 43.12% to -$1.2 million in 2026.
• Business Quant data shows ALT's Change in Account Payables at -$1.2 million in Q1 2026, -$2.1 million in Q4 2025, and $4.0 million in Q3 2025.